Title
Category
Credits
Event date
Cost
Medication Assisted Treatments for Opiates, But What About Stimulants?
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
Telehealth for Substance Use
  • S.U.D
  • 0.50 AAFP Prescribed
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, participants should be able to:
Pregnancy and Women’s SUD
  • S.U.D
  • Women's Health
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objectives:After this course, participants should be able to:
Communication Matters: Motivational Interviewing and Substance Use Disorders
  • S.U.D
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
Screening and Identifying Opioid Use and Substance Use Disorders
  • S.U.D
  • 0.50 AAFP Prescribed
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
MAT and Complex Patients: Addressing Provider Concerns
  • S.U.D
$0.00
Dr. San Bartolome provides case studies and information about managing care for complex patients with addictions who use more than one substance (polysubstance use).Learning Objectives:At the end of this session, learners should be able to:Identify key safety considerations when treating complex, polysubstance use cases for MAT, andExplain 2 strategies for addressing complicated inductions involving methadone and fentanyl.
Opioid and Substance Use Disorders in Special Populations: Youth and Young Adult Athletes
  • S.U.D
  • 1.25 AAFP Prescribed
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
OUD and Stigma: We Can Save Lives
  • S.U.D
$0.00
In this 19 minute presentation, Dr. Gloria Sanchez sheds light on critical and often neglected aspects of opioid use disorder (OUD) stigma encountered by health care professionals and people living with OUD. The medical model of addiction frames addiction as a treatable chronic medical condition rather than a personal failure. While Social Determinants of Health (SDOH) contribute to OUD stigma, we learn what steps providers can take to reduce the negative impacts of stigma and improve OUD care and outcomes.
The Time for Treating Substance Use Disorder Is Now
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
$0.00
People with substance use disorders (SUD) are coming to the office, whether we know it or not. Let's treat SUD/OUD (opioid use disorder) as we would treat any other medical condition: with compassion and good medicine. In this webinar you’ll learn to recognize stigma, communicate more effectively, and be more confident in choosing Medication for OUD (MOUD). Addiction medicine is family medicine.Learning Objective:At the end of this session, learners should be able to:Identify common barriers to health care practitioners beginning MOUD
Break the Stigma, Save a Life
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
$0.00
While gains have been made in reducing stigma around certain conditions, like depression and obesity, little progress has been made in removing the stigma around substance use disorders. The public and even health care providers continue to blame patients for their disease even though there is clear consensus that addiction is a complex brain disorder and not the result of moral weakness and flawed character.When people with addiction are stigmatized and rejected, especially by those within healthcare, it only contributes to the vicious cycle that entrenches their disease.

Pages